Treatment combo beneficial in moderate to severe COPD.
ORLANDO - A combination of fixed-dose mometasone furoate and formoterol fumarate improved lung function in patients with moderate to very severe chronic obstructive pulmonary disease.
The finding came from a 26-week, phase III, multicenter, double-blind, placebo-controlled study of 1,055 adults who were current or former smokers and had a prebronchodilator forced expiratory volume in 1 second (FEVI)/forced vital capacity ratio of 0.70 or less. Currently, three combinations of inhaled corticosteroid plus long-acting beta-agonists are available for the treatment of COPD, but not this particular combination of mometasone furoate with formoterol fumarate administered with a metered-dose inhaler, which is licensed for asthma treatment in the United States under the name Dulera, Dr. Edward Kerwin said at the meeting.
The patients were randomized to one of five twice-daily metered-dose inhaler treatment arms: mometasone furoate 400 mcg/formoterol 10 mcg (MF400/F10), mometasone furoate 200 mcg/formoterol 10 mcg (MF200/F10), mometasone furoate 400 mcg alone (MF400), formoterol 10 mcg alone (F10), or placebo. A total of 840 of the 1,055 randomized patients completed the treatment period. About 80% of the patients were male, with a mean age of 59 years, and about three-quarters were white. Nearly half were current smokers, and all had smoked at one point in time, with an average of 40 pack-years.
The findings of this study also were published online in the International journal of Chronic Obstructive Pulmonary Disease (2012;7:43-55).
One of the two coprimary end points, the contribution of F10 to the MF400/F10 combination at week 13, was reached with a statistically significant 109-mL difference in [FEV.sub.1], area under the curve, compared with MF 400 alone.
The overall effect size was a 163-mL difference for MF400/F10 over placebo at 13 weeks. A comparison of MF 400/F10 with MF 400 monotherapy also demonstrated a statistically significant effect of the F10, with an improvement of 69 mL, reported Dr. Kerwin, of the Clinical Research Institute of Southern Oregon, Medford.
The other coprimary end point, the mean change from baseline in morning predose FE[V.sub.1] at the week 13 end point, showed the contribution of the MF component. It was statistically significant for MF400/F10 over F10 alone, at 111 mL, and for MF200/F10 over F10 alone, at 58 mL. An overall effect size of 128 mL was seen for MF400/F10 over placebo.
Among the secondary efficacy variables, the MF 400/F10 group exceeded the 4-point minimum clinically important difference on the St. George's Respiratory Questionnaire, compared with placebo, with a significant effect size of 4.56 points at week 26. Statistically significant improvements in questionnaire total score for MF400/F10 over placebo were demonstrated at weeks 4, 13, and 26. However, the MF200/F10 dosage did not achieve the minimum clinically important difference, with only a 2.82 reduction, compared with placebo.
The proportion of COPD symptom free nights improved by 0.15 with MF400/F10, compared with 0.06 for placebo, a significant difference over the 26-weekpe-riod. However, there was no treatment difference between MF400/F10 and placebo in the proportion of patients with partly stable COPD at 26 weeks, with percentages ranging from 38% to 46% across treatment groups. Time to first COPD exacerbation significantly improved with MF400/F10 over F10 alone, and an analysis excluding mild exacerbations showed that moderate to severe exacerbations were significantly more frequent with placebo than with MF400/F10, at 16.5% vs. 8.8%, Dr. Kerwin said.
Major Finding: The contribution of F10 to the MF400/F10 combination at week 13 was shown by a statistically significant 109-mL difference in [FEV.sub.1] area under the curve, compared with MF400 alone. The mean change from baseline in morning predose [FEV.sub.1] at the week 13 end point showed the contribution of the MF400 component, with a statistically significant difference of 111 mL between MF400/F10 and F10 alone.
Data Source: The data come from a 26-week, phase Ill, multicenter, double-blind, placebo-controlled study of 1,055 adults with moderate to very severe COPD.
Disclosures: The study was sponsored by Merck Sharp & Dohme. Dr. Kerwin has received consulting fees and/or speaking fees from Dey Labo-ratories, GlaxoSmithKline, MAP Pharma (AstraZeneca), Merck, Teva, and Sepracor.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||PULMONARY MEDICINE|
|Author:||Tucker, Miriam E.|
|Publication:||Internal Medicine News|
|Article Type:||Clinical report|
|Date:||Apr 15, 2012|
|Previous Article:||Biomarkers may aid lung cancer detection.|
|Next Article:||Dengue fever underreported in U.S. travelers.|